Rare diseases and orphan drugs: Latvian story

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Logviss, Konstantins ^a   Krievins, Dainis ^b,c   Purvina, Santa ^a  

^a RIGA STRADINS UNIVERSITY   (Latvia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^c UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Accessibility; Availability; Latvia; Orphan drugs; Rare diseases

Indexed keywords

ORPHAN DRUG;

CONGENITAL HYPOTHYROIDISM; DISEASE REGISTRY; DRUG COST; DRUG UTILIZATION; EUROPE; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HUMAN; LATVIA; NEWBORN SCREENING; PHENYLKETONURIA; RARE DISEASE; REIMBURSEMENT; REVIEW; DRUG LEGISLATION; DRUG MANUFACTURE; ECONOMICS; LEGISLATION AND JURISPRUDENCE; PUBLIC HEALTH; RARE DISEASES; TRENDS;

EUROPE; HUMANS; LATVIA; LEGISLATION, DRUG; NATIONAL HEALTH PROGRAMS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84908159091     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-014-0147-z     Document Type: Review

References (40)

1. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Offic J Europ Communities 2000, L18:1-5. Available from http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF. Accessed 18.04.2014.
2. Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Offic J Europ Communities 2009, C151:7-10. Available from http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF. Accessed 29.01.2014.
3. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe 's challenges. Brussels: Commission of the European Communities; 2008.
4. List of rare disease designations. European Medicines Agency. Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan-seasea.jsp&mid=WC0b01ac058001d12b. Accessed 18.04.2014.
5. European Community Register of designated orphan medicinal products. European Commission. Available from http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm. Accessed 18.04.2014.
6. Aymé S, Rodwell C: 2013 Report on the State of the Art of Rare Disease Activities in Europe. 2013. Available from http://www.eucerd.eu/upload/file/Reports/2013ReportStateofArtRDActivitiesLV.pdf. Accessed 29.01.2014.
7. National Plan for Rare Diseases for the period from 2013 to 2015. Available from http://www.vm.gov.lv/images/userfiles/reto-slimibu-plans-13-15.pdf. Accessed 29.01.2014.
8. Rodwell C, Aymé S: 2014 Report on the State of the Art of Rare Disease Activities in Europe. 2014. Available from http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivitiesV.pdf. Accessed 08.08.2014.
9. Register of the state information systems: Register of patients suffering from certain diseases. Available from https://www.visr.eps.gov.lv/visr/default.aspx?action=2&rid=138. Accessed 29.01.2014.
10. Maternal and infant health care: Statistical yearbook of health care in Latvia. 2012. Available from http://www.spkc.gov.lv/veselibas-aprupesstatistika/.Accessed 18.04.2014.
11. Genome Database of Latvian Population: Latvian Biomedical Research and Study Center. Available from http://biomed.lu.lv/gene/KASirgenomadatubaze.htm. Accessed 29.01.2014.
12. Genome Database of Latvian Population: P3G Catalogue. Available from http://www.p3gobservatory.org/catalogue.htm;jsessionid=ACE6E593F10B80573D64E965FA2DB3D8?measureId=18. Accessed 29.01.2014.
13. Oncological Diseases Control Program for period of 2009-2015. Regulation No. 48 of the Cabinet of Ministers of the Republic of Latvia. Adopted on the 29 January 2009. Available from http://www.epaac.eu/from-heidi-wiki/Latvia---Oncolgical-Diseases-Control-Programme-2009-2015,-Latvi.pdf. Accessed 16.04.2014.
14. Oncology: Statistics on the number of patients by region, types of localization, gender and age groups from 2009 to 2012. Center for Disease Prevention and Control; Updated 22.07.2013. Available from http://www.spkc.gov.lv/veselibas-aprupes-statistika/. Accessed 17.04.2014.
15. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R, RARECARE working group: Rare cancers are not so rare: The rare cancer burden in Europe. Eur J Cancer 2011, 47(17):2493-2511.
16. Cardiovascular Health Improvement Action Plan for period of 2013-2015. Available from http://www.vm.gov.lv/images/userfiles/sirds-plans-07-2013.pdf. Accessed 08.08.2014.
17. Children's Clinical University Hospital: Available from http://www.bkus.lv/page/?main-page-id=&page-type=&second-page-id=&news-id=685. Accessed 29.01.2014.
18. Aymé S, Rodwell C: 2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases. 2012. Available from http://www.eucerd.eu/?post-type=document&p=1501. Accessed 29.01.2014.
19. Rare Disease Registries in Europe. Orphanet Report Series. ; 2014. Available from http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf Accessed 29.01.2014.
20. Children's Health: Statistics of Center for Disease Prevention and Control. 2012. Available from http://www.spkc.gov.lv/veselibas-aprupes-statistika/. Accessed 18.04.2014.
21. Inventory of Community and Member States' incentive measures to aid the research, marketing, development and availability of orphan medicinal products. 2005 revision: 16-17. Available from http://ec.europa.eu/health/files/orphanmp/doc/inventory-2006-08-en.pdf. Accessed 29.01.2014.
22. Cito! Newsletter of State Agency of Medicines of Latvia 2012. 1(48):7-9. Available from http://www.zva.gov.lv/doc-upl/cito-nr48-web.pdf. Accessed 20.04.2014.
23. Order of reimbursement of medicines and medical devices for outpatient treatment. Regulation No. 899 of the Cabinet of Ministers. Riga: 2006. Version of 01.01.2014. Available from http://likumi.lv/doc.php?id=147522. Accessed 29.01.2014.
24. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S: A comparative study of European rare disease and orphan drug markets. Health Policy 2010, 97:173-179.
25. Iskrov G, Miteva-Katrandzhieva T, Stefanov R: Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. Health Policy 2012, 108:10-18.
26. Pavlović N, Stanimirov B, Stojančević M, Paut-Kusturica M, Stoimenova A, Goločorbin-Kon S, Mikov M: An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. Biotechnol Biotec Eq 2012, 26(5):3236-3241.
27. Bignami F: Eurordis survey on orphan drugs availability in Europe. 6th Eurordis Round Table of Companies Workshop. Barcelona: 2007. Available from http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf. Accessed 02.05.2014.
28. Le Cam Y: Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & Eurordis. Paris: 2010. Available from http://img.eurordis.org/newsletter/pdf/mar-2011/ERTC-13122010-YLeCam-Final.pdf. Accessed 02.05.2014.
29. de Varax A, Letellier M, Börtlein G: Study on orphan drugs: Phase I: overview of the conditions for marketing orphan drugs in Europe. Alcimed, Paris: 2004. Available from http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final-final-report-part-1-web-en.pdf. Accessed 02.05.2014.
30. Michel M, Toumi M: Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res 2012, 12(1):23-29.
31. Spokiene I: Legal assessment of current situation on orphan patients in Lithuania. Medicina (Kaunas) 2008, 44(8):571-576.
32. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J: Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007, 23(1):36-42.
33. Picavet E, Dooms M, Cassiman D, Simoens S: Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy 2011, 9(4):275-279.
34. Simoens S: Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011, 6:42.
35. Boon W, Moors E: Exploring emerging technologies using metaphors-a study of orphan drugs and pharmacogenomics. Soc Sci Med 2008, 66:1915-1927.
36. Schey C, Milanova T, Hutchings A: Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis 2011, 6:62.
37. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S: Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ 2010, 13(2):295-301.
38. Orofino J, Soto J, Casado MA, Oyagüez I: Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy 2010, 8(5):301-315.
39. Hutchings A, Schey C, Dutton R, Achana F, Antonov K: Estimating the budget impact of orphan drugs in Sweden and France 2013-2020. Orphanet J Rare Dis 2014, 9:22.
40. Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S: Market uptake of orphan drugs - a European analysis. J Clin Pharm Ther 2012, 37:664-667.